logo
NEW STUDY IDENTIFIES ADDITIONAL LINKS BETWEEN POULTRY ANTIBIOTIC USE AND HUMAN DRUG RESISTANCE

NEW STUDY IDENTIFIES ADDITIONAL LINKS BETWEEN POULTRY ANTIBIOTIC USE AND HUMAN DRUG RESISTANCE

Salisbury, MD, June 25, 2025 (GLOBE NEWSWIRE) — A new
study
, published in mSphere, a journal of the American Society for Microbiology, suggests some antibiotics used in conventional poultry farming may contribute to the development of antibiotic resistance in humans. This research, conducted by Dr. Alex Wong, Asalia Ibrahim and Jason Au of Carleton University's Department of Biology, focuses on ionophores, a class of antibiotics commonly used in conventional poultry farming and previously described as 'not important to human medicine.'
'This research underscores the importance of understanding the interconnectedness of animal and human health,' explains Dr. Alex Wong. 'While ionophores have long been considered safe for use in poultry to prevent parasitic infections, this study suggests that ionophore use could fuel the growth of antibiotic resistance to medically relevant drugs.'
This study highlights the ongoing research and critical discussion about responsible antibiotic use in animal agriculture, showcasing the potentially negative long-term human and animal health effects of using antibiotics in animal production, even those not presently deemed 'important to human medicine.'
The study found:
The study's findings contribute to the ongoing scientific conversation about antibiotic resistance and inform future research and policy decisions and provides evidence that the widespread use of ionophores potentially threaten human health.
'This study surprised me. Personally, I've been dismissing the use of ionophores for years because we didn't have this evidence. This study suggests that it could be driving resistance to the drugs we do care about. When animal producers use ionophores they can drive the growth of bacteria that are resistant to our most important medicines,' Lance Price, M.S. Ph.D., Professor at George Washington's (GW) Milken Institute School of Public Health and Founding Director of GW's Antibiotic Resistance Action Center.
Perdue Takes No Chances with Animal or Human Health, Standing Firm on Its Decade-Long 'No Antibiotics Ever' Commitment
Ionophore use in poultry has been on the rise after a reintroduction of usage by large producers—with some poultry companies relying on routine use of the drug class for preventing illness. However, Perdue Farms took a trailblazing approach by committing to No Antibiotics Ever (NAE) in 2016, shunning the use of all antibiotics including ionophores.
Perdue Farms remains committed to its
No Antibiotics Ever (NAE)
program. 'We started our NAE transition initially due to consumer demand, however with time we have seen, and appreciate, the animal welfare and human health benefits of this approach,' states Dr. Bruce Stewart-Brown, DVM, Chief Science Officer at Perdue Farms. 'For a decade now, our No Antibiotics Ever commitment has reflected our belief that what's good for the bird is also good for people– and this study confirms that belief is well-founded. At the end of the day, it's a promise that gives consumers peace of mind and sets a higher standard for responsible poultry production.'
This research was funded by the Canadian Government, Natural Sciences and Engineering Research Council of Canada (NSERC) and Perdue Farms. Learn more about the study and Perdue Farms' commitment to NAE at
corporate.perduefarms.com
.
For media interested, there will be a virtual briefing today, June 25, at 10 AM ET. You can join that briefing
using this link
starting at 10 AM ET, or reach out to
kerri.mcclimen@perdue.com
for more detail.
###
About Perdue Farms
We're a fourth-generation, family-owned, U.S. food and agriculture company. Through our belief in responsible food and agriculture, we are empowering consumers, customers, and farmers through trusted choices in products and services. Perdue Foods consists of a premium protein portfolio, including our flagship
PERDUE®
brand,
Niman Ranch®
,
Coleman Natural®
,
Pasturebird®
, and
Yummy®
, as well as our pet brands,
Full Moon®
and
Spot Farms®
, and is available through various channels including retail, foodservice, club stores and our direct-to-consumer website,
PerdueFarms.com
.
Perdue AgriBusiness
is a leading merchandiser, processor, and exporter of agricultural products and the largest U.S. manufacturer of specialty, organic, and non-GMO oils. It also ranks as one of the largest suppliers of organic feed ingredients in the world. Now in our company's second century, we never use drugs for growth promotion in raising poultry and livestock, and we are actively advancing our animal welfare programs. Our brands are leaders in no-antibiotics-ever and in USDA-certified organic proteins. Learn more at
Corporate.PerdueFarms.com
.
Attachment

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NEW STUDY IDENTIFIES ADDITIONAL LINKS BETWEEN POULTRY ANTIBIOTIC USE AND HUMAN DRUG RESISTANCE
NEW STUDY IDENTIFIES ADDITIONAL LINKS BETWEEN POULTRY ANTIBIOTIC USE AND HUMAN DRUG RESISTANCE

Hamilton Spectator

time7 hours ago

  • Hamilton Spectator

NEW STUDY IDENTIFIES ADDITIONAL LINKS BETWEEN POULTRY ANTIBIOTIC USE AND HUMAN DRUG RESISTANCE

Salisbury, MD, June 25, 2025 (GLOBE NEWSWIRE) — A new study , published in mSphere, a journal of the American Society for Microbiology, suggests some antibiotics used in conventional poultry farming may contribute to the development of antibiotic resistance in humans. This research, conducted by Dr. Alex Wong, Asalia Ibrahim and Jason Au of Carleton University's Department of Biology, focuses on ionophores, a class of antibiotics commonly used in conventional poultry farming and previously described as 'not important to human medicine.' 'This research underscores the importance of understanding the interconnectedness of animal and human health,' explains Dr. Alex Wong. 'While ionophores have long been considered safe for use in poultry to prevent parasitic infections, this study suggests that ionophore use could fuel the growth of antibiotic resistance to medically relevant drugs.' This study highlights the ongoing research and critical discussion about responsible antibiotic use in animal agriculture, showcasing the potentially negative long-term human and animal health effects of using antibiotics in animal production, even those not presently deemed 'important to human medicine.' The study found: The study's findings contribute to the ongoing scientific conversation about antibiotic resistance and inform future research and policy decisions and provides evidence that the widespread use of ionophores potentially threaten human health. 'This study surprised me. Personally, I've been dismissing the use of ionophores for years because we didn't have this evidence. This study suggests that it could be driving resistance to the drugs we do care about. When animal producers use ionophores they can drive the growth of bacteria that are resistant to our most important medicines,' Lance Price, M.S. Ph.D., Professor at George Washington's (GW) Milken Institute School of Public Health and Founding Director of GW's Antibiotic Resistance Action Center. Perdue Takes No Chances with Animal or Human Health, Standing Firm on Its Decade-Long 'No Antibiotics Ever' Commitment Ionophore use in poultry has been on the rise after a reintroduction of usage by large producers—with some poultry companies relying on routine use of the drug class for preventing illness. However, Perdue Farms took a trailblazing approach by committing to No Antibiotics Ever (NAE) in 2016, shunning the use of all antibiotics including ionophores. Perdue Farms remains committed to its No Antibiotics Ever (NAE) program. 'We started our NAE transition initially due to consumer demand, however with time we have seen, and appreciate, the animal welfare and human health benefits of this approach,' states Dr. Bruce Stewart-Brown, DVM, Chief Science Officer at Perdue Farms. 'For a decade now, our No Antibiotics Ever commitment has reflected our belief that what's good for the bird is also good for people– and this study confirms that belief is well-founded. At the end of the day, it's a promise that gives consumers peace of mind and sets a higher standard for responsible poultry production.' This research was funded by the Canadian Government, Natural Sciences and Engineering Research Council of Canada (NSERC) and Perdue Farms. Learn more about the study and Perdue Farms' commitment to NAE at . For media interested, there will be a virtual briefing today, June 25, at 10 AM ET. You can join that briefing using this link starting at 10 AM ET, or reach out to for more detail. ### About Perdue Farms We're a fourth-generation, family-owned, U.S. food and agriculture company. Through our belief in responsible food and agriculture, we are empowering consumers, customers, and farmers through trusted choices in products and services. Perdue Foods consists of a premium protein portfolio, including our flagship PERDUE® brand, Niman Ranch® , Coleman Natural® , Pasturebird® , and Yummy® , as well as our pet brands, Full Moon® and Spot Farms® , and is available through various channels including retail, foodservice, club stores and our direct-to-consumer website, . Perdue AgriBusiness is a leading merchandiser, processor, and exporter of agricultural products and the largest U.S. manufacturer of specialty, organic, and non-GMO oils. It also ranks as one of the largest suppliers of organic feed ingredients in the world. Now in our company's second century, we never use drugs for growth promotion in raising poultry and livestock, and we are actively advancing our animal welfare programs. Our brands are leaders in no-antibiotics-ever and in USDA-certified organic proteins. Learn more at . Attachment

Cardiovascular Information System Market to Reach USD 2.8 Billion by 2032, Driven by Digital Health Advancements and Growing Cardiac Care Needs
Cardiovascular Information System Market to Reach USD 2.8 Billion by 2032, Driven by Digital Health Advancements and Growing Cardiac Care Needs

Business Upturn

time13 hours ago

  • Business Upturn

Cardiovascular Information System Market to Reach USD 2.8 Billion by 2032, Driven by Digital Health Advancements and Growing Cardiac Care Needs

Austin, June 29, 2025 (GLOBE NEWSWIRE) — Cardiovascular Information System Market Size & Growth Analysis: According to SNS Insider, the Cardiovascular Information System Market was valued at USD 1.24 billion in 2023 and is projected to reach USD 2.8 billion by 2032, growing at a CAGR of 9.4% over the forecast period of 2024–2032. The increasing prevalence of cardiovascular diseases and the need for extensive data management in cardiac care are driving the growth of the global cardiovascular information system market. Emerging technologies including cloud-based solutions, artificial intelligence, and EHR interoperability, are filling clinical workflows. Furthermore, increasing digitization of healthcare, in addition to an improved patient outcomes plan, is anticipated to propel widespread adoption of CVIS across hospitals & specialty care centers. Get a Sample Report of Cardiovascular Information System Market@ The U.S. cardiovascular information system market was estimated at USD 0.33 billion in 2023 and is expected to reach USD 0.73 billion by 2032, at a CAGR of 8.64% during the forecast period of 2024-2032 The North American cardiovascular information system market is dominated by the U.S., attributable to high-end healthcare infrastructure combined with high acceptance of electronic health records and huge investments in digital health technologies. The major CVIS vendors based in this country, coupled with the large number of cardiovascular procedures performed, are continuing to drive the U.S. to a commanding lead in the region. Major Players Analysis Listed in this Report are: Philips Healthcare (IntelliSpace Cardiovascular, Xcelera) Siemens Healthineers (syngo Dynamics, GE Healthcare (Centricity Cardio Enterprise, MUSE Cardiology Information System) McKesson Corporation (McKesson Cardiology, Horizon Cardiology) Agfa Healthcare (IMPAX CV, Enterprise Imaging for Cardiology) Fujifilm Medical Systems (Synapse Cardiovascular, Synapse VNA) LUMEDX Corporation (CardioStar, HealthView CVIS) Cerner Corporation (PowerChart Cardiovascular, CVNet) Merge Healthcare (an IBM Company) (Merge Cardio, Merge Hemo) Digisonics Inc. (DigiView, DigiNet Pro) Cardiovascular Information System Market Report Scope Report Attributes Details Market Size in 2023 US$ 1.24 Billion Market Size by 2032 US$ 2.8 Billion CAGR CAGR of 9.4% From 2024 to 2032 Base Year 2023 Forecast Period 2024-2032 Historical Data 2020-2022 Regional Analysis North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Segment Analysis: Based on the System, the CVIS Segment Leads the Market In 2023, the cardiovascular information system (CVIS) segment held the highest market share due to the fact that it supports the management, storage, and analysis of cardiovascular data from multiple modalities. By enabling image archiving, real-time access, and clinical EHR integration, CVIS boosts workflow efficiency in cardiac care. Use has also grown, due to the growing need for centralized data management and interoperability within healthcare settings. Web-Based Segment Dominates the Market by Mode of Operation The web-based segment accounted for the largest share in 2023 with a 73% market share, owing to the ease with which this type of system can be deployed, its scalability, and cost-effectiveness. These are essential systems for timely decision-making in cardiovascular care, and their connectivity helps provide real-time access to patient data from various locations. Because they demand little to no infrastructure and integrate easily with existing hospital networks, healthcare providers are increasingly opting for a web-based system. By End User, the Hospitals Segment dominated the Cardiovascular Information System Market The hospital segment accounted for the highest share of the CVIS market in 2023. Due to the high number of cardiovascular procedures carried out in a hospital setting, as well as the healthcare organizations' demand for integrated data management systems. SCV and other partners' healthcare professionals, complex imaging workflows, imaging data, and patient records that hospitals manage require comprehensive solutions such as CVIS. For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ Cardiovascular Information System Market Segmentation By Mode Of Operation Web-based Cloud-based On-site By System By End User Hospitals Large Hospitals Medium-sized Hospitals Small Hospitals Diagnostic Centers Regional Trends: North America to Dominate Cardiovascular Information System Market; Asia-Pacific to Witness Fastest Growth The cardiovascular information system (CVIS) market was dominated by North America in 2023, with 37% market share, owing to the high prevalence of cardiovascular diseases, advanced healthcare infrastructure, and early adoption of health IT systems in this region. From the perspective of the growth factors, major industry presence, solid government support & initiatives for EHR, and large investment in hospitals' digitization were a few that complemented the market growth. The Asia-Pacific region is anticipated to exhibit the fastest growth over the forecast period in the cardiovascular information system market. Some of the major factors driving the growth of the cardiovascular diagnostics market are rapid urbanization, increasing healthcare spending, and increasing awareness of the importance of good cardiovascular health. Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 5.1 Adoption Rates of CVIS, 2023 5.2 Device Integration Trends, 2023 5.3 Healthcare Spending on CVIS, by Region, 2023 5.4 Regulatory Compliance and Standardization Trends 5.5 Feature Adoption Trends, 2023 6. Competitive Landscape 7. Cardiovascular Information System Market by Mode Of Operation 8. Cardiovascular Information System Market by System 9. Cardiovascular Information System Market by End User 10. Regional Analysis 11. Company Profiles 12. Use Cases and Best Practices 13. Conclusion Buy a Single-User PDF of Cardiovascular Information System Market Analysis & Outlook Report 2024-2032@ About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

Global Sports Medicine leader Smith+Nephew to sponsor select players competing at Wimbledon, highlighting advanced solutions for joint repair
Global Sports Medicine leader Smith+Nephew to sponsor select players competing at Wimbledon, highlighting advanced solutions for joint repair

Business Upturn

time18 hours ago

  • Business Upturn

Global Sports Medicine leader Smith+Nephew to sponsor select players competing at Wimbledon, highlighting advanced solutions for joint repair

By GlobeNewswire Published on June 29, 2025, 16:00 IST Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces it will once again support select players during high profile matches at The Championships, Wimbledon in 2025. The world's oldest and most prestigious tennis tournament serves as a perfect backdrop to showcase Smith+Nephew's purpose of 'Life Unlimited' – making a difference in patients' lives through the excellence of a diverse Sports Medicine product portfolio and the application of new technologies. Tennis is a high-impact sport that places great stress on various areas of the body – especially joints – often resulting in injury. Some of the latest technologies and solutions from Smith+Nephew for joint repair include: REGENETEN◊ Bioinductive Implant: With more than 150,000 procedures1 completed globally since its introduction in 2014, the REGENETEN Bioinductive Implant has had a transformative impact amongst those having surgery for rotator cuff tears; demonstrating lower re-tear rates than reported compared to conventional techniques.2-6 Backed by level one clinical evidence,2 the collagen-based implant supports the body's natural healing response to facilitate the formation of new tendon-like tissue to biologically augment the existing tendon and change the course of rotator cuff tear progression.7-12 CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant: Derived from a naturally occurring calcium carbonate known as aragonite, the CARTIHEAL Implant is a biphasic scaffold for cartilage repair and subchondral bone restoration.13-15 Shown to deliver clinically meaningful post-operative improvements in pain, function and quality of life,* the CARTIHEAL Implant is the only device approved for the treatment of knee cartilage and osteochondral defects in patients with or without mild to moderate osteoarthritis (KL 0-3).13,16 Q-FIX◊ KNOTLESS All-Suture Anchor: Building on the long-standing success and performance of the Q-FIX Family for best-in-class anchor fixation strength,**,17-21 the new Q-FIX KNOTLESS All-Suture Anchor raises the bar for all-suture anchor technology. With proprietary features and capabilities, the Q-FIX KNOTLESS All-Suture Anchor aims to set a new benchmark for soft tissue security†,22 and offer surgeons a new option for soft tissue-to-bone fixation indications across multiple joint spaces. 'Our inaugural turn sponsoring select players during The Championships, Wimbledon in 2024 was a tremendous success supporting athletes from across the globe – including Jasmine Paolini all the way to the Ladies Final,' said Christie van Geffen, SVP Global Sports Medicine Marketing for Smith+Nephew. 'We were able to uniquely feature the Smith+Nephew brand along with our leading Sports Medicine technology portfolio – designed to help weekend warriors and world-class athletes get back to competing and doing what they love.' If you would like to learn more about Smith+Nephew's leading Sports Medicine technology portfolio – including the CARTIHEAL AGILI-C Cartilage Repair Implant, the REGENETEN Bioinductive Implant and the Q-FIX KNOTLESS All-Suture Anchor – please visit here. – ends – Media Enquiries Dave Snyder +1 (978) 749-1440 Smith+Nephew [email protected] *Over a 2 and 4 year follow up **As compared to competitive devices in fixation/pull-out benchtop testing †As compared to the competitive device in cyclic benchtop testing References Smith+Nephew. Internal Data. Ruiz Ibán MÁ, García Navlet M, Moros Marco S, et al. Augmentation of a Transosseous-Equivalent Repair in Posterosuperior Nonacute Rotator Cuff Tears With a Bioinductive Collagen Implant Decreases the Retear Rate at One Year: A Randomized Controlled Trial. Arthroscopy: The Journal of Arthroscopic & Related Surgery. 2023:1-14. Bushnell BD, Connor PM, Harris HW, et al. Retear rates and clinical outcomes at 1 year after repair of full-thickness rotator cuff tears augmented with a bioinductive collagen implant: a prospective multicenter study. JSES international. 2021;5(2):228. Hein J, Reilly JM, Chae J, Maerz T, Anderson K. Retear Rates After Arthroscopic Single-Row, Double Row, and Suture Bridge Rotator Cuff Repair at a Minimum of 1 Year of Imaging Follow-up: A Systematic Review. Arthroscopy. 2015;31(11):2274-2281. Camacho-Chacon JA, Cuenca-Espierrez J, Roda-Rojo V, et al. Bioinductive collagen implants facilitate tendon regeneration in rotator cuff tears. J Exp Orthop. 2022;9(1):53. Smith + Nephew overview of the outcomes associated with the standard of care for the surgical treatment of rotator cuff tears. Internal Report EO/SPM/REGENETEN/005/v1. Bokor DJ, Sonnabend D, Deady L, et al. Evidence of healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a collagen implant: a 2-year MRI follow-up. Muscles, Ligaments Tendons J. 2016;6(1):16-25. Schlegel TF, Abrams JS, Bushnell BD, Brock JL, Ho CP. Radiologic and clinical evaluation of a bioabsorbable collagen implant to treat partial-thickness tears: a prospective multicenter study. J Shoulder Elbow Surg. 2018 27(2):242-251. Van Kampen C, Arnoczky S, Parks P, et al. Tissue-engineered augmentation of a rotator cuff tendon using a reconstituted collagen scaffold: a histological evaluation in sheep. Muscles Ligaments Tendons J. 2013;3(3):229-235. Arnoczky SP, Bishai SK, Schofield B, et al. Histologic Evaluation of Biopsy Specimens Obtained After Rotator Cuff Repair Augmented With a Highly Porous Collagen Implant. Arthroscopy. 2017;33(2):278-283 Bokor DJ, Sonnabend DH, Deady L, et al. Healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a highly porous collagen implant: a 5-year clinical and MRI follow-up. Muscles, Ligaments Tendons J. 2019;9(3):338-347. McElvany MD, McGoldrick E, Gee AO, Neradilek MB, Matsen FA, 3rd. Rotator cuff repair: published evidence on factors associated with repair integrity and clinical outcome. Am J Sports Med. 2015;43(2):491-500. Altschuler N, Zaslav KR, Di Matteo B, et al. Aragonite-Based Scaffold Versus Microfracture and Debridement for the Treatment of Knee Chondral and Osteochondral Lesions: Results of a Multicenter Randomized Controlled Trial. Am J Sports Med. 2023;51(4):957-967. doi:10.1177/03635465231151252 Kon E, Di Matteo B, Verdonk P, et al. Aragonite-Based Scaffold for the Treatment of Joint Surface Lesions in Mild to Moderate Osteoarthritic Knees: Results of a 2-Year Multicenter Prospective Study. Am J Sports Med. 2021;49(3):588-598. Kon E, Filardo G, Shani J, et al. Osteochondral regeneration with a novel aragonite-hyaluronate biphasic scaffold: up to 12-month follow-up study in a goat model. J Orthop Surg Res. 2015;10:81. Conte P, Anzillotti G, Crawford DC, et al. Differential analysis of the impact of lesions' location on clinical and radiological outcomes after the implantation of a novel aragonite-based scaffold to treat knee cartilage defects. Int Orthop. 2024;48(12):3117-3126 Douglass NP, et al. Arthroscopy. 2017;33(5):977-985 e975. Ergun S, et al. Arthroscopy. 2020; 2(3):e263-e275. Smith+Nephew 2023. Internal Report. 10090792- Revision B. ArthroCare Corporation 2017. Internal Report. P/N 49190-03 Rev. B. Smith+Nephew 2024. Internal Report. 10144423 Rev B. Smith and Nephew 10144423 Rev B About Smith+Nephew Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise. For more information about Smith+Nephew, please visit and follow us on X, LinkedIn, Instagram or Facebook. Forward-looking Statements This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as 'aim', 'plan', 'intend', 'anticipate', 'well-placed', 'believe', 'estimate', 'expect', 'target', 'consider' and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC's website at www. for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations. ◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store